Chlorambucil in chronic lymphocytic leukemia: Mechanism of action

被引:67
作者
Begleiter, A
Mowat, M
Israels, LG
Johnston, JB
机构
[1] Manitoba Institute of Cell Biology, Manitoba Cancer Treatm. Res. Found., University of Manitoba, Winnipeg, Man.
[2] Manitoba Institute of Cell Biology, Winnipeg, Man. R3E 0V9
基金
英国医学研究理事会;
关键词
chlorambucil; chronic lymphocytic leukemia; mechanisms; sensitivity; resistance;
D O I
10.3109/10428199609054821
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries but the clinical presentation and rate of disease progression are highly variable. When treatment is required the most commonly used therapy is the nitrogen mustard alkylating agent, chlorambucil (CLB), with or without prednisone. Although CLB has been used in the treatment of CLL for forty years the exact mechanism of action of this agent in CLL is still unclear. Studies in proliferating model tumor systems have demonstrated that CLB can bind to a variety of cellular structures such as membranes, RNA, proteins and DNA; however, DNA crosslinking appears to be most important for antitumor activity in these systems. In addition, a number of different mechanisms can contribute to CLB resistance in these tumor models including increased drug metabolism, DNA repair and CLB detoxification resulting from elevated levels of glutathione (GSH) and glutathione S-transferase (GST) activity. However, unlike tumor models in vitro, CLL cells are generally not proliferating and studies in CLL cells have raised questions about the hypothesis that DNA crosslinking is the major mechanism of antitumor action for CLB in this disease. CLB induces apoptosis in CLL cells and this appears to correlate with the clinical effects of this agent. Thus, alkylation of cellular targets other than DNA, which can also induce apoptosis, may contribute to the activity of CLB. Alterations in genes such as p53, mdm-2, bcl-2 and bax which control entry into apoptosis may cause drug resistance. Loss of wild-type p53 by mutation or deletion occurs in 10 to 15% of CLL patients and appears to correlate strongly with poor clinical response to CLB. The induction of apoptosis by CLB is paralleled by an increase in P53 and Mdm-2 but this increase is not observed in patients with p53 mutations indicating that with high drug concentrations CLB can produce cell death through P53 independent pathways. The level of Mdm-2 mRNA in the CLL cells is not a useful predictor of drug sensitivity. In addition, although Fax and Bcl-2 are important regulators of apoptosis and the levels of these proteins are elevated in CLL cells compared with normal B cells, the levels of Fax and Bcl-2, or the Bax:Bcl-2 ratio, are not important determinants of drug sensitivity in this leukemia. Finally, whereas CLB and nucleoside analogs may produce cell death in CLL by a P53 dependent pathway other agents, such as dexamethasone or vincristine, may act through P53-independent pathways.
引用
收藏
页码:187 / +
页数:1
相关论文
共 96 条
  • [1] PREFERENTIAL LINKAGE OF BCL-2 TO IMMUNOGLOBULIN LIGHT CHAIN GENE IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    ADACHI, M
    TEFFERI, A
    GREIPP, PR
    KIPPS, TJ
    TSUJIMOTO, Y
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (02) : 559 - 564
  • [2] ARRICK BA, 1984, CANCER RES, V44, P4224
  • [3] BANK BB, 1989, CANCER RES, V49, P554
  • [4] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [5] BEGLEITER A, 1994, LEUKEMIA, V8, pS103
  • [6] UPTAKE AND DECOMPOSITION OF CHLORAMBUCIL BY L5178Y-LYMPHOBLASTS INVITRO
    BEGLEITER, A
    GOLDENBERG, GJ
    [J]. BIOCHEMICAL PHARMACOLOGY, 1983, 32 (03) : 535 - 539
  • [7] MECHANISMS OF RESISTANCE TO CHLORAMBUCIL IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    BEGLEITER, A
    GOLDENBERG, GJ
    ANHALT, CD
    LEE, K
    MOWAT, MRA
    ISRAELS, LG
    JOHNSTON, JB
    [J]. LEUKEMIA RESEARCH, 1991, 15 (11) : 1019 - 1027
  • [8] BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
  • [9] 2-V
  • [10] BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH
    BOISE, LH
    GONZALEZGARCIA, M
    POSTEMA, CE
    DING, LY
    LINDSTEN, T
    TURKA, LA
    MAO, XH
    NUNEZ, G
    THOMPSON, CB
    [J]. CELL, 1993, 74 (04) : 597 - 608